- Open Access
Correction to: CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Cancer Cell International volume 20, Article number: 521 (2020)
- The original article was published in Cancer Cell International 2020 20:456
Correction to: Cancer Cell Int (2020) 20:456 https://doi.org/10.1186/s12935-020-01546-8
Following publication of the original article , we were notified the Department of Virology, Pasteur Institute of Iran should have been mentioned as the only affiliation for the first and last author. The revised affiliation is reflected in this correction article.
Miri SM, et al. CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. Caner Cell Int. 2020;20:456. https://doi.org/10.1186/s12935-020-01546-8.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Miri, S.M., Tafsiri, E., Cho, W.C.S. et al. Correction to: CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. Cancer Cell Int 20, 521 (2020). https://doi.org/10.1186/s12935-020-01609-w